PledPharma AB (PLED):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C7578)
◆英語タイトル:PledPharma AB (PLED) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7578
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年10月
◆ページ数:40
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:スウェーデン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥26,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥52,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥78,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
PledPharma AB (PledPharma) is a pharmaceutical company that discovers, manufactures, and develops drugs that protect the body against oxidative stress. The company discovers and develops Aladote and PledOx drugs. Its PledOX drug is used to prevent chemotherapy-induced side effects for colorectal cancer. PledPharma’s products are also used in the therapeutic areas such as oncology and cardiology. The company also evaluates derivatives for conditions related to oxidative stress during treatment of life threatening diseases and also develops pharmaceuticals based on PLED substances. It also provides treatment for life-threatening illnesses based on the PLED technologies. PledPharma is headquartered in Stockholm, Sweden.

PledPharma AB (PLED) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
PledPharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
PledPharma AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
PledPharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
PledPharma AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
PledPharma AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
PledPharma AB, Pharmaceuticals & Healthcare, Deal Details 10
Licensing Agreements 10
Solasia Pharma Enters into Licensing Agreement with PledPharma 10
Equity Offering 11
PledPharma Raises USD46 Million in Rights offering of Shares 11
PledPharma Raises USD10 Million in Rights Offering of Shares 12
PledPharma AB – Key Competitors 13
PledPharma AB – Key Employees 14
PledPharma AB – Locations And Subsidiaries 15
Head Office 15
Recent Developments 16
Financial Announcements 16
Aug 22, 2018: PledPharma: half-year report january-june 2018 16
Apr 24, 2018: PledPharma: Interim Report January-March 2018 18
Feb 22, 2018: PledPharma: Year-end Report January-December 2017 20
Oct 20, 2017: Pledpharma: Interim report January – September 2017 22
Aug 30, 2017: PledPharma: Interim report January – June 2017 23
Apr 25, 2017: PledPharma: Interim report January – March 2017 25
Feb 24, 2017: PledPharma: Year end report January – December 2016 26
Corporate Communications 27
Apr 13, 2018: PledPharma announces Head of CMC and Supply Chain 27
Nov 07, 2017: PledPharma appoints Yilmaz Mahshid as new CFO 28
Sep 15, 2017: PledPharma’s CFO to leave the company in December 2017 29
Aug 17, 2017: PledPharma appoints a Chief Medical Officer 30
Jun 29, 2017: PledPharma appoints vice president product strategy and development 31
Jun 16, 2017: Nicklas Westerholm takes office as CEO of PledPharma 32
Apr 06, 2017: PledPharma Appoints Nicklas Westerholm as New CEO 33
Product News 34
06/29/2017: PledPharma strengthens the management team with a Vice President Product Strategy and Development 34
Clinical Trials 35
Dec 01, 2017: First patient included in Phase I study aiming at supporting expansion of global Phase III program for PledOx to include Asian patients 35
Nov 17, 2017: PledPharma’s Phase IIb study with PledOx (PLIANT) published in Acta Oncologica 36
Nov 16, 2017: PledPharma initiates Phase III studies with PledOx before year end 2017 37
Sep 14, 2017: The Aladote study in patients treated for paracetamol overdose is now open for recruitment for the next dosage group 38
Jun 08, 2017: First patient included in PledPharma’s clinical trial with Aladote 39
Appendix 40
Methodology 40
About GlobalData 40
Contact Us 40
Disclaimer 40

List of Tables
PledPharma AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2
PledPharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
PledPharma AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
PledPharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
PledPharma AB, Deals By Therapy Area, 2012 to YTD 2018 8
PledPharma AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Solasia Pharma Enters into Licensing Agreement with PledPharma 10
PledPharma Raises USD46 Million in Rights offering of Shares 11
PledPharma Raises USD10 Million in Rights Offering of Shares 12
PledPharma AB, Key Competitors 13
PledPharma AB, Key Employees 14

List of Figures
PledPharma AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
PledPharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
PledPharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
PledPharma AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
PledPharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
PledPharma AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
PledPharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
PledPharma AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ PledPharma AB (PLED):製薬・医療:M&Aディール及び事業提携情報(PledPharma AB (PLED) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆